Tarsus Pharmaceuticals Cash Flow Statement
NASDAQ: TARSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Tarsus Pharmaceuticals free cash flow
In fiscal 2025, Tarsus Pharmaceuticals generated -$12.5 million of operating cash flow and spent $9.9 million on capital expenditures. That left free cash flow of -$22.3 million, a free-cash-flow margin of -4.9% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Tarsus Pharmaceuticals cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -66.42M | -115.55M | -135.89M | -62.09M | -13.83M | -26.81M | -4.67M | -1.32M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 855.00K | 685.00K | 744.00K | 326.00K | 300.00K | 100.00K | 37.00K | — |
| Stock-Based Compensation | 41.72M | 27.82M | 19.83M | 13.46M | 8.46M | 839.00K | 18.00K | — |
| Change in Working Capital | -40.05M | -32.19M | -22.62M | -721.00K | -2.04M | -2.46M | -18.00K | — |
| Operating Cash Flow | -12.45M | -83.03M | -117.49M | -49.03M | 3.75M | -21.14M | -3.67M | — |
| Capital Expenditures | -9.86M | -1.57M | -1.50M | -506.00K | -586.00K | -456.00K | -175.00K | — |
| Investing Cash Flow | -42.12M | -199.19M | 140.60M | -144.63M | -586.00K | -456.00K | -175.00K | — |
| Debt Issued | 0 | 75.00M | 10.00M | 20.00M | — | — | — | — |
| Financing Cash Flow | 143.39M | 154.66M | 130.18M | 93.99M | 21.00K | 131.77M | 59.45M | — |
| Net Change in Cash | 88.82M | -127.57M | 153.29M | -99.67M | 3.18M | 110.18M | 55.60M | — |
| Free Cash Flow | -22.31M | -84.59M | -119.00M | -49.54M | 3.16M | -21.59M | -3.85M | — |
This table shows 8 annual periods of Tarsus Pharmaceuticals's cash flow statement, from FY 2025 back to FY 2018, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow TARS's reporting calendar. What is a cash flow statement?